On this page you can find relevant researchs on drug-related health topics, including HIV, hepatitis C, drug and overdose prevention, harm reduction and drug treatment. You can also find our Clinical Guidelines.

Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery
Healthcare professionals are crucial in the identification and accessibility to treatment for people with substance use disorders. Our objective was to assess health professionals’ attitudes towards patients with substance use disorders and examine the consequences of these attitudes on healthcare delivery for these patients in Western countries.
Decriminalize all drug possession? Not a bad idea: Editorial
NDP leadership Jagmeet Singh’s decriminalization proposal, while politically bold, reflects a view that is relatively uncontroversial among public health experts. (DARRYL DYCK / THE CANADIAN PRESS)
Playing relationship counsellor – can we avert a divorce between scientific evidence and drug policy?
Nowhere is the divorce between rhetoric and reality more evident than in the formulation of global drug policies, where too often emotions and ideology rather than evidence have prevailed.
A Stocktake Review of DFID’s Work on HIV and AIDS
Reframing the War on Drugs – a Conversation with German Lopez
“In the middle of us continuing mass incarceration and a tough war on drugs we are having the worst drug epidemic in US history. If these policies actually worked we would never had this epidemic, let alone the worst one ever. Yet here we are….” – German Lopez, Vox
Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review
The burden of hepatitis C virus (HCV) infection is escalating among people who inject drugs (PWID), yet testing and treatment remains suboptimal. The aim of this systematic review was to evaluate the effectiveness of interventions to enhance HCV testing, linkage to care, and treatment uptake among PWID.
Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy
This special issue published in the International Journal of Drug Policy includes original research articles, systematic and expert reviews, and commentaries focused on the “Elimination of hepatitis C virus infection among PWID: the beginning of a new era of interferon-free DAA therapy”.
Kirketon Road Centre (KRC)
Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
Risk of hepatocellular carcinoma (HCC) occurrence or recurrence following direct-acting antiviral (DAA) HCV therapy remains unclear. This study however concludes there is no evidence to support withholding DAA therapy in patients with HCV-related cirrhosis or after curative HCC management.
US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations
US opioid overdose death rates have increased between 2000 and 2014. This study documents the differences in trends in prescription opioid overdose-related (POD) and heroin overdose related (HOD) hospitalizations.
Share this on: